 Recent advancements in biologics have shown promise for treating severe asthma cases. In this study, researchers found that 68.5% of patients achieved complete remission, CR, and 31.5% achieved deep remission, DR. Patients who achieved CR had a longer history of asthma, lower adult onset asthma rates, and higher forced expiratory volume in one second, FEV1, measurements compared to those who did not. Additionally, patients with shorter asthma duration and higher FEV1 measurements had better chances of achieving CR and DR. The authors concluded that the early introduction of biologics in severe asthma patients could be beneficial in helping them achieve CR and DR. This article was authored by Keiji Oishi, Kazuki Hamada, Yoriyuki Murata, and others.